Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SMMT · as of Sep 30, 2025
Ownership Breakdown
257
Institutional Holders
▲ 5 vs Q2
$2.12B
Total Inst. Value
▲ $44.35M vs Q2
775.37M
Shares Outstanding
freeFloat 13.83%
102.88M
13F Shares Held
▲ 5.02M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SMMT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP pharmaceutical preparations | 33.72M | 4.54% | 4.54% | $696.72B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 11.38M | 1.53% | 1.53% | $235.11B | Nov 7, 2025 | ▲ 2.71M |
FMR LLC pharmaceutical preparations | 8.92M | 1.20% | 1.20% | $184.24B | Nov 13, 2025 | ▼ 308.5K |
BLACKROCK, INC. pharmaceutical preparations | 7.36M | 99.16% | 99.16% | $152.14B | Nov 12, 2025 | ▲ 517.1K |
STATE STREET CORP pharmaceutical preparations | 6.36M | 85.67% | 85.67% | $131.44B | Nov 14, 2025 | ▲ 2.34M |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 4.54M | 61.12% | 61.12% | $93.77B | Nov 14, 2025 | ▲ 633.7K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.13M | 42.19% | 42.19% | $64.74B | Nov 12, 2025 | ▲ 197.9K |
MORGAN STANLEY pharmaceutical preparations | 1.93M | 25.95% | 25.95% | $39.81B | May 27, 2026 | ▲ 1.28M |
PICTET ASSET MANAGEMENT HOLDING SA pharmaceutical preparations | 1.60M | 21.60% | 21.60% | $33.50B | Nov 18, 2025 | ▼ 559.7K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 1.39M | 18.74% | 18.74% | $28.75B | Nov 14, 2025 | ▲ 345.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
30
Increased
+11.67M shares4
New Positions
first time holders11
Decreased
−2.86M shares0
Sold Out
fully exitedNet shares change (top 50)
+8.81M
+11.67M / −2.86M
Net new holders
+23
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SMMT insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
DUGGAN ROBERT W Co-Chief Executive Officer | Jun 4, 2026 | Purchase | 100,000 | $14.60 | $1.46M | 25.82M | Form 4 ↗ |
Zanganeh Mahkam Co-Chief Executive Officer | Jun 4, 2026 | Purchase | 100,000 | $14.60 | $1.46M | 25.82M | Form 4 ↗ |
Soni Manmeet Singh COO and CFO | Jun 4, 2026 | Purchase | 25,000 | $14.43 | $360.8K | 3.12M | Form 4 ↗ |
Soni Manmeet Singh COO and CFO | Jun 4, 2026 | Purchase | 25,000 | $14.46 | $361.5K | 3.10M | Form 4 ↗ |
Anand Bhaskar Chief Accounting Officer | Jan 8, 2026 | Award | 30,000 | $18.83 | $564.9K | 30.0K | Form 4 ↗ |
Zanganeh Mahkam Co-Chief Executive Officer | Jan 2, 2026 | Award | 11,232 | $17.52 | $196.8K | 11.2K | Form 4 ↗ |
DUGGAN ROBERT W Co-Chief Executive Officer | Jan 2, 2026 | Award | 11,232 | $17.52 | $196.8K | 11.2K | Form 4 ↗ |
Booth Robert F. director | Jan 2, 2026 | Award | 35,000 | $17.52 | $613.2K | 35.0K | Form 4 ↗ |
Booth Robert F. director | Jan 2, 2026 | Award | 7,180 | $17.52 | $125.8K | 7.2K | Form 4 ↗ |
Xia Yu director | Jan 2, 2026 | Award | 35,000 | $17.52 | $613.2K | 35.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Summit Therapeutics Inc. (SMMT) is primarily owned by institutional investors, who hold approximately 13.3% of total shares outstanding. Company insiders own approximately 86.17%, while retail and public investors account for the remaining 0.56%.
The largest institutional shareholder of Summit Therapeutics Inc. is BAKER BROS. ADVISORS LP, holding approximately 33.72 million shares — equal to 4.54% of outstanding shares — as of September 30, 2025.
A total of 257 institutional investors currently hold SMMT stock, with a combined institutional value of approximately $2.12 billion as of the most recent 13F filing period.
Frequently asked questions
SMMT ownershipSummit Therapeutics Inc. (SMMT) is primarily owned by institutional investors, who hold approximately 13.3% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 4.54% stake. Company insiders hold 86.17%. Data sourced from SEC Form 13F as of September 30, 2025.